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β-Defensins
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Abstract
Human β-defensins (hBDs) stimulate degranulation in rat peritoneal mast cells in vitro and cause
increased vascular permeability in rats in vivo. In this study, we sought to determine whether hBDs
activate murine and human mast cells and to delineate the mechanisms of their regulation. hBD2 and
hBD3 did not induce degranulation in murine peritoneal or bone marrow-derived mast cells (BMMC) in
vitro and had no effect on vascular permeability in vivo. By contrast, these peptides induced sustained
Ca2+ mobilization and substantial degranulation in human mast cells, with hBD3 being more potent.
Pertussis toxin (PTx) had no effect on hBD-induced Ca2+ mobilization, but La3+ and
2-aminoethoxydiphenyl borate (a dual inhibitor of inositol 1,4,5-triphosphate receptor and transient
receptor potential channels) caused substantial inhibition of this response. Interestingly, degranulation
induced by hBDs was substantially inhibited by PTx, La3+, or 2-aminoethoxydiphenyl borate. Whereas
human mast cells endogenously express G protein-coupled receptor, Mas-related gene X2 (MrgX2), rat
basophilic leukemia, RBL-2H3 cells, and murine BMMCs do not. Silencing the expression of MrgX2 in
human mast cells inhibited hBD-induced degranulation, but had no effect on anaphylatoxin C3a-induced
response. Furthermore, ectopic expression of MrgX2 in RBL-2H3 and murine BMMCs rendered these cells
responsive to hBDs for degranulation. This study demonstrates that hBDs activate human mast cells via
MrgX2, which couples to both PTx-sensitive and insensitive signaling pathways most likely involving Gαq
and Gαi to induce degranulation. Furthermore, murine mast cells are resistant to hBDs for degranulation,
and this reflects the absence of MrgX2 in these cells. Copyright©2013 by The American Association of
Immunologists, Inc.
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b-Defensins Activate Human Mast Cells via Mas-Related
Gene X2
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Hydar Ali

uman b-defensins (hBDs) are small cationic antimicrobial peptides (AMPs) that are produced by epithelial cells
and platelets and play an important role in host defense (1,
2). Of the four members of this family (hBD1–4), hBD-1 is constitutively expressed, whereas the others are induced by bacteria,
viruses, and cytokines. In addition to their host defense functions,
hBD2 and hBD3 display immunomodulatory properties and induce
the expression of costimulatory molecules on dendritic cells in a
TLR-dependent manner (3, 4). Furthermore, they promote chemotaxis of CD4+ T lymphocytes and macrophages via the activation
of chemokine receptor, CCR2 (5, 6). hBD3 causes the recruitment of
CD11c+ dendritic cell precursors via CCR6 into tumorigenic locations where VEGF-A transforms them into endothelial cells, resulting in neovascularization, tumor development, and progression (7).
Mast cells are multifunctional immune cells, and in humans two
subtypes are recognized based on the composition of their secretory
granules (8, 9). Thus, mast cell granules that contain both tryptase
and chymase are designated MCTC, whereas those containing only
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tryptase are known as MCT. Rat peritoneal mast cells (PMCs)
display phenotypic and functional properties similar to human
MCTC, and both hBD2 and hBD3 induce degranulation in these
cells (10, 11). Moreover, hBD3 causes increased cutaneous vascular permeability in wild-type, but not mast cell–deficient Ws/Ws
rats (11). Studies with pertussis toxin (PTx) indicated the involvement of G proteins, but the G protein–coupled receptors
(GPCRs) via which hBDs activate rat mast cells remain unknown
(11). We have recently shown that the antimicrobial peptide LL-37
activates human mast cells via a novel GPCR, known as MrgX2
(12). This raises the interesting possibility that hBDs can also
activate human mast cells via MrgX2 or a related GPCR (13).
However, the possibility that hBDs activate primary murine mast
cells has not been reported.
The purpose of the current study was to determine whether hBD2
and hBD3 activate murine and human mast cells and to determine
the mechanisms of their regulation. Surprisingly, we found that
murine mast cells are resistant to activation by hBDs in vitro and
in vivo. By contrast, hBDs caused degranulation in human mast
cells via MrgX2, which couples to both PTx–sensitive and insensitive G proteins, most likely Gaq and Gai.

Received for publication January 4, 2013. Accepted for publication April 30, 2013.
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Materials

Address correspondence and reprint requests to Dr. Hydar Ali, Department of Pathology, University of Pennsylvania School of Dental Medicine, 240 South 40th
Street, Philadelphia, PA 19104-6030. E-mail address: alih@upenn.edu
Abbreviations used in this article: AMP, antimicrobial peptide; 2-APB, 2-aminoethoxydiphenyl borate; BMMC, bone marrow–derived mast cell; CST, cortistatin;
GFX, bisindolylmaleimide; GPCR, G protein–coupled receptor; HA, hemagglutinin;
hBD, human b-defensin; mCRAMP, mouse cathelin-related AMP; PKC, protein
kinase C; PMC, peritoneal mast cell; PTx, pertussis toxin; rhIL, human rIL; rhSCF,
recombinant human stem cell factor; shRNA, short hairpin RNA.
Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1300023

Frozen human G-CSF–mobilized peripheral blood CD34+ progenitors were
obtained from the Fred Hutchinson Cancer Center (Seattle, WA). All cell
culture reagents and PTx were purchased from Invitrogen (Gaithersburg,
MD). Amaxa transfection kit (Kit V) was purchased from Lonza (Gaithersburg, MD). All recombinant human cytokines were purchased from
PeproTech (Rocky Hill, NJ). Cortistatin (CST)-14 was obtained from
American Peptide (Vista, CA). Native complement C3a was from Complement Technology (Tyler, TX). LL-37 and mouse cathelin-related AMP
(mCRAMP) was from Anaspec (Freemont, CA). hBD2 and hBD3 were
from Peptide International (Louisville, KY). MrgX2 Ab was purchased from
Novus Biologicals (Littleton, CO). Bisindolylmaleimide (GFX; GF109203X)
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Human b-defensins (hBDs) stimulate degranulation in rat peritoneal mast cells in vitro and cause increased vascular permeability
in rats in vivo. In this study, we sought to determine whether hBDs activate murine and human mast cells and to delineate the
mechanisms of their regulation. hBD2 and hBD3 did not induce degranulation in murine peritoneal or bone marrow–derived mast
cells (BMMC) in vitro and had no effect on vascular permeability in vivo. By contrast, these peptides induced sustained Ca2+
mobilization and substantial degranulation in human mast cells, with hBD3 being more potent. Pertussis toxin (PTx) had no effect
on hBD-induced Ca2+ mobilization, but La3+ and 2-aminoethoxydiphenyl borate (a dual inhibitor of inositol 1,4,5-triphosphate
receptor and transient receptor potential channels) caused substantial inhibition of this response. Interestingly, degranulation
induced by hBDs was substantially inhibited by PTx, La3+, or 2-aminoethoxydiphenyl borate. Whereas human mast cells endogenously express G protein–coupled receptor, Mas-related gene X2 (MrgX2), rat basophilic leukemia, RBL-2H3 cells, and murine
BMMCs do not. Silencing the expression of MrgX2 in human mast cells inhibited hBD-induced degranulation, but had no effect
on anaphylatoxin C3a-induced response. Furthermore, ectopic expression of MrgX2 in RBL-2H3 and murine BMMCs rendered
these cells responsive to hBDs for degranulation. This study demonstrates that hBDs activate human mast cells via MrgX2, which
couples to both PTx-sensitive and insensitive signaling pathways most likely involving Gaq and Gai to induce degranulation.
Furthermore, murine mast cells are resistant to hBDs for degranulation, and this reflects the absence of MrgX2 in these cells. The
Journal of Immunology, 2013, 191: 345–352.
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and 2-aminoethoxydiphenyl borate (2-APB) were obtained from Santa Cruz
Biotechnology (Dallas, TX).

Generation of murine bone marrow–derived mast cells and
PMCs
Bone marrow–derived mast cells (BMMCs) were obtained by flushing
bone marrow cells from the femurs of C57BL/6 mice (The Jackson Laboratory) and culturing the cells for 4–6 wk in IMDM supplemented with
10% FCS, L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100
mg/ml), and murine IL-3 (10 ng/ml) (PeproTech). Peritoneal cells were
collected from mice injected (i.p.) with 2 ml IMDM complete medium.
Cells were seeded at 1 3 106/ml in complete IMDM supplemented with
murine stem cell factor (10 ng/ml) and murine IL-3 (10 ng/ml). BMMCs
and PMCs were used within 4–8 wk.

Passive cutaneous anaphylaxis

FIGURE 1. hBDs do not induce degranulation in
murine mast cells in vitro or in vivo. (A) Amino acid
sequences of hBD2, hBD3, CST, LL-37, and mCRAMP.
Positively charged amino acids are underlined. (B) Murine PMCs or (C) BMMCs were incubated with mouse
IgE (1 mg/ml, 16 h) and then stimulated with hBD2
(5 mM), hBD3 (3 mM), or Ag (DNP-BSA, 100 ng/ml),
and degranulation was determined. (D) For IgE-mediated
passive cutaneous anaphylaxis, C57BL/6 mice or mast
cell–deficient Wsh/Wsh mice were passively sensitized in
the ear with PBS (open white bars) or IgE (closed black
bars) (20 ng for 16 h) and challenged with an i.v. injection of a 100 mg Ag (DNP-BSA) in 200 ml PBS
containing 1% Evans blue. For defensin, C57BL/6 mice
were i.v. injected with 200 ml 0.5% Evans blue before
intradermal injection of hBD3 (closed black bars) (150
ng) into one side of the ear and vehicle PBS (open white
bars) into the other ear. The mice were killed 30 min
after injection, and Evans blue dye contents in the ear
tissues were measured. The results are expressed as
ODA650/g tissue. Data shown are representative of three
similar experiments. Statistical significance was determined by two-way ANOVA with Bonferroni’s posttest.
*p , 0.01.

Differentiation of human mast cells from CD34+ progenitors
and culture of human mast cell lines
To generate primary mast cells, human CD34+ progenitors were cultured
in StemPro-34 medium (Life Technologies, Rockville, MD) supplemented
with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 mg/
ml), recombinant human stem cell factor (rhSCF) (100 ng/ml), human rIL
(rhIL)-6 (100 ng/ml), and rhIL-3 (30 ng/ml) (first week only). Hemidepletions were performed weekly with media containing rhSCF (100 ng/
ml) and rhIL-6 (100 ng/ml) (15). Cells were used for experiments after
7–10 wk in culture. LAD2 cells were maintained in complete StemPro34 medium supplemented with 100 ng/ml rhSCF (16). RBL-2H3 and
HEK293 cells were maintained as monolayer cultures in DMEM supplemented with 10% FBS, L-glutamine (2 mM), penicillin (100 IU/ml), and
streptomycin (100 mg/ml) (17).

Lentivirus-mediated knockdown of MrgX2 in LAD2 mast cells
MrgX2-targeted Mission short hairpin RNA (shRNA) lentiviral plasmids
were purchased from Sigma-Aldrich. The clone that gave the highest
knockdown efficiency (TRCN0000009174) was used (12). A nontarget
vector (SHC002) was used as a control. Lentivirus generation was performed, according to the manufacturer’s manual. Cell transduction was
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Four- to 6-wk-old C57BL/6 mice and C57BL/6J-KitW-sh (Wsh/Wsh) mice
weighing 20–22 g were used throughout the study. All animal experiments
were performed according to a protocol approved by the Institutional
Animal Care and Use Committee that conforms to the ethical standards
formulated in the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health. Induction of passive cutaneous anaphylaxis was performed as described previously with minor
modifications (14). Briefly, anti–DNP-BSA–specific IgE (Sigma-Aldrich;
SPE-7, 20 ng) was intradermally injected into the mouse left ear, or PBS as
a control in the right ear. After 24 h, mice were challenged with an i.v.
injection of 100 mg Ag (DNP-BSA) in 200 ml PBS containing 1% Evans
blue (Sigma-Aldrich) through the tail vein. Thirty minutes following the
Ag challenge, the mice were euthanized; the ears were removed, weighed,

dissolved in 500 ml formamide, and incubated at 55˚C overnight. After
shaking, the supernatant was collected by centrifugation at 4000 3 g for 10
min, and absorbance was measured at 650 nm. For some experiments, mice
were i.v. injected with 200 ml 1% Evans blue 5 min before intradermal
injection of hBD3 (150 ng) in left ear and vehicle PBS in the right ear.
After 30 min, mice were euthanized, and absorbance of Evans blue extracted from mouse ear was determined.

The Journal of Immunology
conducted by mixing 1.5 ml viral supernatant with 3.5 ml LAD2 (5 3 106)
cells. Eight hours postinfection, medium was changed to virus-free complete medium, and antibiotic (puromycin, 4 mg/ml; Sigma-Aldrich) selection was initiated 16 h later. Cells were analyzed for MrgX2 knockdown
by Western blotting.

Transfection of RBL-2H3, HEK293 cells, and BMMCs

Calcium mobilization
Ca2+ mobilization was determined, as described previously (17). Briefly, cells
(human mast cells; 0.2 3 106, RBL-2H3 and HEK293 cells; 1.0 3 106) were
loaded with 1 mM indo-1 AM for 30 min at room temperature. Cells were
washed and resuspended in 1.5 ml HEPES-buffered saline. Ca2+ mobilization
was measured in a Hitachi F-2500 spectrophotometer with an excitation
wavelength of 355 nm and an emission wavelength of 410 nm (20).

Degranulation
BMMCs and PMCs were sensitized overnight with anti-DNP mouse IgE
(SPE-7, 1 mg/ml) in cytokine-free medium. The cells were rinsed three

FIGURE 2. hBDs induce degranulation and Ca2+
mobilization in LAD2- and CD34+-derived human mast
cells. LAD2 mast cells were stimulated with different
concentrations of (A) hBD2 or (C) hBD3, and percentage
of degranulation (b-hexosaminidase release) was determined. Data are mean 6 SEM of three experiments. (B
and D) LAD2 cells were loaded with indo-1 AM, and
Ca2+ mobilization in response to hBD2 or hBD3 was
determined. (E) CD34+ cell-derived primary mast cells
were exposed to different concentrations of hBD3, and
degranulation was determined. (F) CD34+ cell-derived
mast cells were loaded with indo-1, and Ca2+ mobilization in response to hBD3 was determined. Data shown
are representative of three similar experiments. Statistical
significance was determined by two-way ANOVA with
Bonferroni’s posttest. *p , 0.01, **p , 0.001.

times with buffer containing BSA (Sigma-Aldrich) to remove excess IgE.
Human mast cells (5 3 103) and RBL-2H3 cells (5 3 104) were seeded
into 96-well plates in a total volume of 50 ml HEPES buffer containing
0.1% BSA and exposed to different concentrations of peptides. In some
assays, cells were pretreated with PTx (EMD Millipore, Billerica, MA;
100 ng/ml for 16 h) or La3+ (lanthanum chloride, 1 mM for 5 min). For
total b-hexosaminidase release, unstimulated cells were lysed in 50 ml
0.1% Triton X-100. Aliquots (20 ml) of supernatant or cell lysates were
incubated with 20 ml 1 mM p-nitrophenyl-N-acetyl-b-D-glucosamine for
1.5 h at 37˚C. Reaction was stopped by adding 250 ml 0.1 M Na2CO3/0.1
M NaHCO3 buffer, and absorbance was measured at 405 nm (17).

Results
Effects of hBDs on murine mast cells in vitro and in vivo
hBD2 and hBD3 are small cationic peptides that play an important
role in innate immunity by directly killing microbes (21). Compared
with hBD2, hBD3 contains more positive charges and possesses
a broader spectrum of antimicrobial activity (Fig. 1A) (22). In rat
PMCs, both hBD2 and hBD3 induce degranulation in a dosedependent manner, with hBD2 being more potent (11, 23). We
therefore sought to determine whether these peptides also induce
degranulation in murine mast cells. For these studies, we tested the
effects of hBDs on degranulation in murine PMCs and BMMCs. As
shown in Fig. 1B and 1C, whereas Ag caused substantial degranulation in both types of mast cells, hBD2 (5 mM) and hBD3 (3 mM)
were without effect. Local cutaneous administration of hBD3 (150
ng) increases vascular permeability in wild-type rats, but this response was absent in mast cell–deficient Ws/Ws rats (11). We
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RBL-2H3 cells were transfected with plasmids encoding hemagglutinin
(HA)-tagged MrgX2 using the Amaxa nucleofector device and Amaxa kit
V, according to the manufacturer’s protocol. HEK293 cells were transfected with the same plasmid using Lipofectamine reagent (Invitrogen).
Following transfection, cells were cultured in the presence of G-418 (1
mg/ml), and cells expressing equivalent receptors were sorted using an
FITC-conjugated anti-HA–specific Ab (12CA5) and used for studies on
Ca2+ mobilization and degranulation (18, 19).
Mature BMMCs (2.0 3 106) were transfected with plasmids encoding
HA-tagged MrgX2 (3 mg) using the Amaxa nucleofector device and Amaxa
kit V (program T020). Twenty-four hours following transfection, cells were
used for degranulation studies.
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found that mouse IgE and Ag caused a passive cutaneous anaphylactic reaction in wild-type C57BL/6 mice and that this response was absent in mast cell–deficient Wsh/Wsh mice (Fig. 1D).
However, hBD3 did not induce increased vascular permeability in
C57BL/6 mice. These findings clearly demonstrated that, unlike
the situations in rats (10, 11), hBDs do not induce degranulation in
murine mast cells in vitro or in vivo.
hBD2 and hBD3 induce degranulation in human mast cells

Role of PTx-sensitive G protein–dependent and independent
pathways on hBD2/3-induced degranulation
In rat PMCs, hBD2- and hBD3-induced Ca2+ mobilization and
degranulation are inhibited by PTx (10, 11). The signaling pathway via which hBD2 and hBD3 induce degranulation in human
mast cells is unknown. We first tested the effects of PTx on hBD2and hBD3-induced Ca2+ mobilization in LAD2 mast cells. We

hBD2 and hBD3 activate human mast cells via MrgX2
hBDs activate dendritic cells, T cells, and monocytes via CCR2 and
CCR6 and TLRs (3, 5, 29). However, in rat PMCs, hBD-induced
responses are not mediated via CCR6 (30). Furthermore, RBL2H3 cells stably expressing CCR6 are unresponsive to hBD2 and
hBD3 (31). In addition, we found that CCL2, a ligand for CCR2,
failed to induce Ca2+ mobilization in LAD2 mast cells (data not
shown). These findings clearly demonstrate that effects of hBDs in
human mast cells are mediated independently of CCR2 or CCR6.
It is noteworthy that mast cells are the only known cells outside

FIGURE 3. Effects of PTx and La3+ on C3a-, hBD2-, and hBD3-induced Ca2+ mobilization and degranulation in human mast cells. (A and E) Indo-1–
loaded LAD2 cells were exposed to C3a, followed by hBD2 or hBD3, and intracellular Ca2+ mobilization was determined. (B and F) Cells were treated with
PTx (100 ng/ml, 16 h), and effects of C3a, hBD2, or hBD3 on Ca2+ mobilization were determined. (C and G) Indo-1–loaded LAD2 cells were exposed to
La3+ (lanthanum chloride, 1 mM), and C3a-, hBD2-, or hBD3-induced Ca2+ mobilization was determined. Traces are representative of three independent
experiments. (D and H) LAD2 mast cells were exposed to buffer (control) or PTx (100 ng/ml, 16 h) or (La3+ (lanthanum chloride, 1 mM, 30 min), and C3a-,
hBD2-, and hBD3-induced degranulation was determined. Data are mean 6 SEM of three experiments. Statistical significance was determined by two-way
ANOVA with Bonferroni’s posttest. **p , 0.001.
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In rat PMCs, hBD2 is more potent in inducing degranulation than
hBD3 (10, 11). We therefore sought to determine the dose-response effects of these AMPs on degranulation in human mast
cells using LAD2 cells, which are widely used as a model to study
human mast cell function in vitro. We found that, unlike the situation with rat mast cells, but consistent with greater net positive
charge on hBD3 (Fig. 1A), it was more potent than hBD2 in inducing degranulation in LAD2 cells. Thus, hBD2, at a concentration of 1 mM, caused ∼20% degranulation, but hBD3 at the same
concentration caused ∼75% response (Fig. 2A, 2C). This difference in the extent of degranulation correlated with a greater Ca2+
mobilization by hBD3 than hBD2 (Fig. 2B, 2D). To confirm the
biological relevance of the studies with LAD2 cells, we repeated
selected experiments in CD34+-derived primary human mast cells.
We found that, as for LAD2 cells, hBD3 induced degranulation in
CD34+-derived mast cells, but the magnitude of the response was
∼50% lower (Fig. 2C, 2E). Interestingly, hBD3 induced a Ca2+
response in CD34+-derived human mast cells that was similar in
profile to that observed in LAD2 cells (Fig. 2D, 2F).

used the anaphylatoxin C3a as a control, which is known to induce
a Ca2+ response via a PTx-sensitive G protein. We found that
whereas C3a-induced Ca2+ response was substantially blocked by
PTx, it had little or no effect on the response to hBD2 or hBD3
(Fig. 3A, 3B, 3E, 3F). La3+, an inhibitor of Ca2+ release-activated
Ca2+ channels, has been shown to inhibit both Ca2+ influx and
mast cell degranulation (24, 25). We found that La3+ had no effect
on the early Ca2+ spike in response to C3a, but it completely
blocked the Ca2+ responses to both hBD2 and hBD3 (Fig. 3C,
3G). Interestingly, treatment of cells with either PTx or La3+ almost completely blocked degranulation induced by C3a, hBD2,
and hBD3 (Fig. 3D, 3H). These findings demonstrate that, unlike
the situation in rat mast cells, hBD2 and hBD3 cause degranulation in human mast cells via the interaction of a Gai-independent
Ca2+ influx and an unknown Gai-mediated pathway, most likely
via protein kinase C (PKC) (17). We used a pharmacologic approach to test this possibility. The 2-APB inhibits mast cell degranulation via its action as a dual inhibitor of inositol 1,4,5triphosphate receptor and transient receptor potential channels
(26–28). We found that 2-APB blocked both the initial Ca2+ spike
and the sustained Ca2+ influx in response to hBD3, and this was
associated with a substantial inhibition of degranulation (Fig. 4A,
4B, 4D). By contrast, a PKC inhibitor, GFX, had little or no effect
on hBD3-induced Ca2+ mobilization, but caused significant inhibition of degranulation (Fig. 4A, 4C, 4D).
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the dorsal ganglia that express MrgX2 (32). Furthermore, this
receptor is activated by basic peptides, including the amphipathic
antimicrobial peptide, LL-37 (12, 32). To determine whether
hBDs activate human mast cells via MrgX2, we used shRNA
to silence the expression of MrgX2 in LAD2 mast cells (12).
We found that MrgX2-shRNA caused a substantial reduction in
the expression of MrgX2 when compared with control shRNAtransduced cells (Fig. 5A). Furthermore, hBD2-, hBD3-, and
CST (a known ligand for MrgX2)-induced degranulation was
significantly inhibited in MrgX2-silenced cells when compared
with shRNA control. By contrast, degranulation to C3a, which
activates mast cells via C3aR, was not affected (Fig. 5B). We have
previously shown that native RBL-2H3 cells, which are highly
responsive to Ag/IgE for degranulation, do not endogenously express MrgX2 and are unresponsive to MrgX2 ligands such as
CST unless the cells are transfected with cDNA encoding MrgX2
(18, 19). To further confirm the role of MrgX2 on hBD-induced
degranulation, we used RBL-2H3 cells stably expressing human
MrgX2 (18). In this system, hBD2, hBD3, and CST induced
substantial mast cell degranulation (Fig. 6A), and this was associated with increased intracellular Ca2+ mobilization (Fig. 6B–D).
hBD3 and CST also induced Ca2+ mobilization in HEK293 cells
stably expressing MrgX2 (Fig. 6E, 6F), but this response was
absent in untransfected cells (data not shown).
Previous studies showed that human b-defensins and the human cathelicidin LL-37 induce signaling and degranulation in rat
PMCs (11, 33). However, the resistance of murine PMCs or BMMCs
to human antimicrobial peptides (Fig. 1B, 1C) could reflect the
inability of human peptides to activate a murine Mrg receptor.
Murine analogs of human antimicrobial peptides are not well
characterized, with the exception of mCRAMP, which is the
murine analog of human LL-37 (34–36). We have recently shown
that LL-37 induces human mast cell degranulation via MrgX2
(12). To test the possibility that mCRAMP could activate mast
cells via MrgX2, we transiently expressed HA-MrgX2 in murine
BMMCs and confirmed cell surface expression via flow cytometry
(Fig. 7A). Cells expressing MrgX2 responded to mCRAMP,
hBD3, and CST with an increased degranulation response as compared with control vector-transfected BMMCs (Fig. 7B). In ad-

dition, mCRAMP caused substantial Ca2+ mobilization and dosedependent degranulation in LAD2 mast cells (Fig. 7C, 7D). Collectively, these data suggest that hBDs, LL-37, and mCRAMP
activate mast cells via MrgX2 and that resistance of native murine
PMCs and BMMCs reflects the absence of this receptor in mouse
mast cells.

Discussion
hBDs are multifunctional AMPs produced by epithelial cells and
platelets and promote innate immunity, adaptive immunity, angiogenesis, and tumor metastasis, and modulate sepsis (1, 37).
Most of the effects of hBDs in immune cells appear to be mediated via the activation of TLRs, CCR2, and CCR6 (4–6, 38). hBDs
have been shown to induce chemotaxis and degranulation in rat
PMCs (10, 11, 31). Given the functional heterogeneity that exists
between mast cells of different species (39–41), data obtained

FIGURE 5. Knockdown of MrgX2 inhibits hBD2, hBD3, and cortistatin,
but not C3a-induced mast cell degranulation. LAD2 mast cells were stably
transduced with scrambled shRNA control lentivirus or shRNA lentivirus
targeted against MrgX2. (A) Western blotting was performed to determine
MrgX2 expression in control and MrgX2 knockdown (KD) cells. (B)
shRNA control and MrgX2 KD cells were stimulated with hBD2, hBD3,
CST, or C3a, and percentage of degranulation (b-hexosaminidase release)
was determined. Data are mean 6 SEM of three experiments. Statistical
significance was determined by one-way ANOVA with Bonferroni’s posttest. *p , 0.01, **p , 0.001.
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FIGURE 4. Effects of 2-APB and GFX on hBD3induced Ca2+ mobilization and degranulation in human
mast cells. (A–C) Indo-1–loaded LAD2 cells were left
untreated (control) or pretreated with 2-APB or GFX,
and hBD3-induced Ca2+ mobilization was determined.
Traces are representative of three independent experiments. (D) LAD2 mast cells were pretreated with
buffer control or 2-APB or GFX, and degranulation
response to hBD3 was determined. Data are mean 6
SEM of three experiments. Statistical significance was
determined by one-way ANOVA with Bonferroni’s
posttest. *p , 0.01.
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with rat mast cells may not replicate in mouse and human mast
cells. In the current study, we demonstrate that hBD2 and hBD3
do not activate murine mast cells, but induce substantial degranulation in human mast cells. Our studies also demonstrate that G
protein and signaling pathways via which hBDs activate human
mast cells are different from those reported for rat mast cells and
may reflect differences in the activation of cell surface receptors.
In this study, we identify MrgX2 as a novel GPCR via which
hBD2 and hBD3 activate human mast cells.
Mrg receptors belong to the GPCR family, and, in humans, four
Mrg genes, MrgX1–X4, are known (13, 42). Although originally
thought to be specifically expressed in dorsal root ganglia, it now
appears that human skin mast cells, cord blood–derived mast cells,
CD34+ cell-derived mast cells, and a human mast cell line, LAD2,
express MrgX2 (18, 32, 43). Most interestingly, this receptor is not
present in human lymph node, spleen, or peripheral blood leukocytes (32). In fact, of the 42 human cell types tested, only mast
cells express MrgX2 (32). hBD2 and hBD3 are amphipathic
peptides, and, given the recent demonstration that MrgX2 serves
as a receptor for a variety of cationic peptides (18, 32), we hy-

pothesized that it could serve as a receptor for hBDs in human
mast cells. Indeed, three lines of evidence clearly support this
contention. First, LAD2 and CD34+ cell-derived human mast cells
that endogenously express MrgX2 responded to hBDs for Ca2+
mobilization and degranulation. Second, shRNA-mediated silencing of MrgX2 caused a significant decrease of hBD2- and
hBD3-induced responses. Third, ectopic expression of MrgX2 in
RBL-2H3 cells, murine BMMCs, and HEK293 cells renders these
cells responsive to hBDs.
Consistent with previous reports in rat PMCs (10), we found
that hBD2- and hBD3-induced degranulation in human mast cells
is inhibited by PTx. However, an important difference was that
whereas hBD2-induced Ca2+ influx in rat PMCs was blocked by
PTx (10), it had no effect on the Ca2+ response in human mast cells.
It is noteworthy that MrgX2 couples to Gaq family of G proteins
for Ca2+ mobilization in transfected HEK293 cells (44). We found
that La3+ or 2-APB blocked hBD3-induced Ca2+ mobilization and
degranulation. By contrast, a PKC inhibitor, which had little or no
effect on hBD3-induced Ca2+ mobilization, caused significant inhibition of degranulation. This raises the interesting possibility
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FIGURE 6. hBDs activate RBL2H3 and HEK293 cells expressing
MrgX2. (A) RBL-2H3 cells stably
expressing MrgX2 were stimulated
with buffer, hBD2, hBD3, or CST for
30 min, and b-hexosaminidase release was measured. Data shown are
representative of three similar experiments. Statistical significance was determined by one-way ANOVA with
Bonferroni’s posttest. **p , 0.001.
RBL-2H3 cells stably expressing
MrgX2 were loaded with indo-1
AM, and Ca2+ mobilization in response to (B) hBD2, (C) hBD3, or
(D) CST was determined. HEK293
cells stably expressing MrgX2 were
loaded with indo-1 AM, and Ca2+
mobilization in response to (E) hBD3
or (F) CST was determined. Traces
shown are representative of three individual experiments.
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that, unlike the situation in rat mast cells, hBDs activate Gaq to
promote Ca2+ mobilization (inhibited by La3+ and 2-APB) and that
this response functions in concert with PTx-sensitive signals, at
least in part via PKC, to promote degranulation in human mast
cells. The reason for the difference in specificity of hBDs for
G protein coupling between rat and human mast cells is unknown,
but could reflect the utilization of different GPCRs. Interestingly,
unlike most GPCRs, Mrg receptors display substantial speciesspecific differences. Thus, human Mrg receptors share only 45–
65% amino acid sequence identity with rat receptors. In addition,
whereas there are only four Mrg genes known in humans, the rat
genome possesses one each of the MrgA, MrgC, and MrgD genes
and 10 MrgB genes (45). Rat PMCs express a number of Mrg
receptors, including MrgB1, MrgB2, MrgB3, MrgB6, MrgB8, and
MrgB9. Furthermore, basic peptides induce Ca2+ mobilization only
in HEK293 cells expressing MrgB3 (32). Thus, whereas hBD2
and hBD3 activate human mast cells via MrgX2, it is likely that
they activate rat PMCs via MrgB3, and this difference is reflected
in the differences in G protein–coupling specificities.
A surprising observation of the current study was that, unlike
the situation in human mast cells, hBDs did not induce degranulation in murine PMCs in vitro and had no effect on skin mast cell
in vivo as measured by changes in vascular permeability. Because
human defensins were used throughout this study, it is possible that
the resistance of murine mast cells reflects differences between
humans and murine peptides. This possibility is, however, unlikely.
In addition to hBDs, the human cathelicidin LL-37 also activates
degranulation in rat and human mast cells (33, 46). We have recently shown that LL-37 induces degranulation in human mast
cells via MrgX2 (12). The murine analog of human LL-37
(mCRAMP) displays biological activities very similar to those of
LL-37 (47). In the current study, we have shown that mCRAMP
causes Ca2+ mobilization and degranulation in human mast cells.
Furthermore, transfection of murine BMMCs with cDNA encoding MrgX2 renders them responsive to CST, LL-37, hBD3, and
mCRAMP for degranulation. These findings suggest that hBDs

and LL-37 activate human mast cells via MrgX2 and that the
resistance of murine mast cells reflects absence of this receptor
in murine mast cells (13, 42).
This study has important implications for mast cell–mediated
host defense. Rapid mast cell degranulation following bacterial
infection provides an important mechanism for host defense
in vivo (48). It has been proposed that, following bacterial infection, the anaphylatoxins C3a and C5a are generated, which
cause mast cell degranulation and contribute to the recruitment of
neutrophils at the site of infection. Given that the anaphylatoxins
induce degranulation from both human and murine mast cells (14,
49), the initial mechanism for the mast cell activation in the
context of innate immunity is likely to be similar for both humans
and mice. However, mast cell degranulation induces hBD2 and
hBD3 in human epithelial cells (50), which most likely contributes
to further human mast cell degranulation via MrgX2. This suggests that innate function of mast cells most likely involves two
phases, one mediated by anaphylatoxins and the other defensins.
The differences between the abilities of AMPs to activate human
and murine mast cells suggest important species-specific differences in the mechanism of regulation of innate immunity.

Acknowledgments
We thank Drs. Arnold Kirshenbaum and Dean Metcalfe (National Institute of Allergy and Infectious Diseases/National Institutes of Health) for
providing LAD2 mast cells and the FACS core facilities of the Schools of
Medicine and Dental Medicine, University of Pennsylvania, for acquisition, analysis, and cell sorting.

Disclosures
The authors have no financial conflicts of interest.

References
1. Weinberg, A., G. Jin, S. Sieg, and T. S. McCormick. 2012. The yin and yang of
human beta-defensins in health and disease. Front. Immunol. 3: 294.

Downloaded from http://www.jimmunol.org/ at Univ of Pennsylvania Library on August 17, 2022

FIGURE 7. hBD3 and mCRAMP activate
murine BMMCs expressing MrgX2. (A)
BMMCs were transiently transfected with
HA-tagged MrgX2 (solid line) or control
plasmid vector (broken line), and MrgX2
receptor expression level was analyzed using flow cytometry. A representative histogram is shown. (B) Control and MrgX2
expressing BMMCs were incubated with
DNP-specific mouse IgE (1 mg/ml, 16 h).
Cells were exposed to buffer (control), CST,
hBD3, mCRAMP, or DNP-BSA (10 ng/ml)
for 30 min, and b-hexosaminidase release
was measured. LAD2 cells were stimulated
with mCRAMP, and (C) intracellular Ca2+
mobilization or (D) degranulation was determined. Traces are representative of three
independent experiments. Bar graphs represent mean 6 SEM of three experiments.
Statistical significance was determined by
one-way ANOVA with Bonferroni’s posttest. *p , 0.01.

352

DEFENSINS AND MrgX2 IN HUMAN MAST CELL ACTIVATION
26. Schindl, R., H. Kahr, I. Graz, K. Groschner, and C. Romanin. 2002. Store
depletion-activated CaT1 currents in rat basophilic leukemia mast cells are
inhibited by 2-aminoethoxydiphenyl borate: evidence for a regulatory component that controls activation of both CaT1 and CRAC (Ca(2+) release-activated
Ca(2+) channel) channels. J. Biol. Chem. 277: 26950–26958.
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